参考文献/References:
[1] Samman Tahhan A, Vaduganathan M, Greene SJ, et al. Evolving landscape of clinical trials in heart failure: patient populations, endpoint selection, and regions of enrollment[J]. Curr Heart Fail Rep, 2018, 15(1):10-16.
[2] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure[J]. Rev Esp Cardiol (Engl Ed), 2016,74(10):1037-1147.
[3] Zannad F, Garcia AA, Anker SD, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document[J]. Eur J Heart Fail,2013,15(10):1082-1094.
[4] Ghali JK, Orlandi C, Abraham WT, et al. The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study[J]. Eur J Heart Fail,2012,14(6):642-651.
[5] Laurent G, Eicher JC, Mathe A, et al. Permanent left atrial pacing therapy may improve symptoms in heart failure patients with preserved ejection fraction and atrial dyssynchrony: a pilot study prior to a national clinical research program[J]. Eur J Heart Fail,2013,15(1):85-93.
[6] Jaarsma T, Klompstra L,Ben Gal T, et al. Increasing exercise capacity and quality of life of patients with heart failure through Wii gaming: the rationale, design and methodology of the HF-Wii study;a multicentre randomized controlled trial[J]. Eur J Heart Fail,2015,17(7):743-748.
[7] Assmus B, Walter DH, Seeger FH, et al. Effect of shock wave-facilitated intracoronary cell therapy on LVEF in patients with chronic heart failure: the CELLWAVE randomized clinical trial[J]. JAMA,2013,309(15):1622-1631.
[8] Latini R, Masson S, Anand I, et al. Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure:the Valsartan Heart Failure Trial (Val-HeFT)[J]. Circulation,2002,106(19):2454-2458.
[9] Bhardwaj A,Rehman SU,Mohammed A,et al. Design and methods of the Pro-B Type Natriuretic Peptide Outpatient Tailored Chronic Heart Failure Therapy(PROTECT) Study[J]. Am Heart J,2010,159(4):532-538.
[10] Januzzi JL,Richards AM. Natriuretic Peptide-guided heart failure therapy after the GUIDE-IT study[J]. Circulation,2018,137(20):2101-2103.
[11] Maeder MT,Rickenbacher P,Rickli H,et al. N-terminal pro brain natriuretic peptide-guided management in patients with heart failure and preserved ejection fraction:findings from the Trial of Intensified versus standard medical therapy in elderly patients with congestive heart failure (TIME-CHF)[J]. Eur J Heart Fail,2013,15(10):1148-1156.
[12] Jirak P,Fejzic D,Paar V,et al. Influences of ivabradine treatment on serum levels of cardiac biomarkers sST2, GDF-15, suPAR and H-FABP in patients with chronic heart failure[J]. Acta Pharmacol Sin,2018,39(7):1189-1196.
[13] Konstam MA. Progress in heart failure Management? Lessons from the real world[J]. Circulation,2000,102(10):1076-1078.
[14] U.S. Department of Health and Human Services FDA Center for Drug Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Biologics Evaluation and Research, U.S. Department of Health and Human Services FDA Center for Devices and Radiological Health. Guidance for industry:patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance[J]. Health Qual Life Outcomes,2006,4(1):79.
[15] Kelkar AA, Spertus J, Pang P, et al. Utility of patient-reported outcome instruments in heart failure[J]. JACC Heart Fail,2016,4(3):165-175.
[16] Filippatos G,Maggioni AP,Lam CSP,et al. Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study[J]. Eur J Heart Fail,2017,19(6):782-791.
[17] Br?nnstr?m M,Boman K. Effects of person-centred and integrated chronic heart failure and palliative home care. PREFER:a randomized controlled study[J]. Eur J Heart Fail,2014,16(10):1142-1151.
[18] Bekelman DB,Plomondon ME,Carey EP,et al. Primary Results of the Patient-Centered Disease Management(PCDM) for Heart Failure Study: A Randomized Clinical Trial[J]. JAMA Intern Med,2015,175(5):725-732.
[19] Tian J,?Xue J,?Hu X, et al. CHF-PROM: validation of a patient-reported outcome measure for patients with chronic heart failure[J]. Health Qual Life Outcomes,2018,16(1):51.
[20] Tromp J, Tay WT, Ouwerkerk W, et al. Multimorbidity in patients with heart failure from 11 Asian regions: a prospective cohort study using the ASIAN-HF registry[J]. PLoS Med,2018,15(3):e1-e22.
[21] Lam CSP, Gamble GD, Ling LH, et al. Mortality associated with heart failure with preserved vs. reduced ejection fraction in a prospective international multi-ethnic cohort study[J]. Eur Heart J,2018,39(20):1770-1780.
[22] Chin KL,Collier TJ,Pitt B,et al. Aspirin does not reduce the clinical benefits of the mineralocorticoid receptor antagonist eplerenone in patients with systolic heart failure and mild symptoms:an analysis of the EMPHASIS-HF study[J]. Eur J Heart Fail,2016,18(9):1175-1181.
[23] Moss AJ, Hall WJ, Cannom DS, et al. Improved?survival?with an implanted defibrillator in patients?with?coronary disease at high risk for ventricular arrhythmia.Multicenter Automatic?Defibrillator?Implantation Trial Investigators[J]. N Engl J Med,1996,335(26):1933-1940.
[24] Chen CY, Stevenson LW, Stewart GC, et al. Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities:cohort study of older patients with heart failure[J]. BMJ, 2015,351:h3529.
[25] Elder DH, Singh JS, Levin D, et al. Mean HbA1c and mortality in diabetic individuals with heart failure:a population cohort study[J]. Eur J Heart Fail,2016,18(1):94-102.
[26] Cannon JA,Collier TJ,Shen L,et al. Clinical outcomes according to QRS duration and morphology in the Eplerenone in Mild Patients: Hospitalization and SurvIval Study in Heart Failure (EMPHASIS-HF)[J]. Eur J Heart Fail,2015,17(7):707-716.
[27] R?rth R,Wong C,Kragholm K,et al. Return to the Workforce After First Hospitalization for Heart Failure: A Danish Nationwide Cohort Study[J]. Circulation,2016,134(14): 999-1009.
[28] Greene SJ,O’Brien EC,Mentz RJ,et al. Home-time after discharge among patients hospitalized with heart failure[J]. J Am Coll Cardiol,2018,71(23):2643-2652.
[29] Florea VG,Rector TS,Anand IS,et al. Heart Failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival:results from the Valsartan Heart Failure Trial[J]. Circ Heart Fail,2016,9(7):pii: e003123.
[30] Baruch L,Glazer RD,Aknay N,et al. Morbidity,mortality,physiologic and functional parameters in elderly and non-elderly patients in the Valsartan Heart Failure Trial (Val-HeFT)[J]. Am Heart J,2004,148(6): 951-957.
[31] Linde C,Gold MR,Abraham WT,et al. Long-term impact of cardiac resynchronization therapy in mild heart failure:5-year results from the REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction(REVERSE) study[J]. Eur Heart J,2013,34(33):2592-2599.
[32] Gaggin HK,Mohammed AA,Bhardwaj A,et al. Heart failure outcomes and benefits of NT-proBNP-guided management in the elderly:results from the prospective, randomized ProBNP outpatient tailored chronic heart failure therapy(PROTECT) study[J]. J Card Fail,2012,18(8):626-634.
[33] Weiner RB,Baggish AL,Chen-Tournoux A,et al. Improvement in structural and functional echocardiographic parameters during chronic heart failure therapy guided by natriuretic peptides:mechanistic insights from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) study[J]. Eur J Heart Fail,2013,15(3):342-351.
相似文献/References:
[1]戴玫,付珞,胡建英,等.慢性心力衰竭患者应用高强度间歇性有氧训练研究进展[J].心血管病学进展,2016,(3):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
DAI Mei,FU Luo,HU Jianying,et al.Advances in Research on High-intensity Interval Training in Chronic Heart Failure[J].Advances in Cardiovascular Diseases,2016,(6):271.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.014]
[2]张培,综述,刘剑,等.慢性心力衰竭并发肌少症的研究进展[J].心血管病学进展,2016,(3):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
ZHANG Pei,LIU Jian.Research Progress in Chronic Heart Failure-induced Sarcopenia[J].Advances in Cardiovascular Diseases,2016,(6):275.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.015]
[3]杨颜瑜,苏星,谭敏,等.炎症指标与急性心肌梗死研究进展[J].心血管病学进展,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
YANG Yanyu,SU Xing,TAN Min,et al.Relationship Between Inflammation Index and Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(6):947.[doi:10.16806/j.cnki.issn.1004-3934.2019.0.027]
[4]于子凯 许海燕 刘庆荣 吴永健.合并常见疾病对经导管主动脉瓣置换术患者预后的影响[J].心血管病学进展,2019,(5):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
YU Zikai,XU Haiyan,LIU Qingrong,et al.Influence of ommon Accompanied Diseases on Prognosis of Patients after Transcatheter Aortic Valve Replacement[J].Advances in Cardiovascular Diseases,2019,(6):697.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.009]
[5]崔小豪 杨志明.和肽素在急性心肌梗死中的研究进展[J].心血管病学进展,2019,(5):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
CUI Xiaohao,YANG Zhiming.Copeptin in Acute Myocardial Infarction[J].Advances in Cardiovascular Diseases,2019,(6):726.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.016]
[6]陈文浩 张焕基 郭攸胜 张东辉.活检证实病毒性心肌炎的治疗策略及预后[J].心血管病学进展,2019,(5):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
Chen WenhaoZhang HuanjiGuo YoushengZhang Donghui.Treatment Strategy and Prognosis of Viral Myocarditis Confirmed by Biopsy[J].Advances in Cardiovascular Diseases,2019,(6):813.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.037]
[7]王振伟 王涟 徐标.应激性心肌病患者临床特点及预后分析[J].心血管病学进展,2019,(5):831.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.041]
WANG Zhenwei,WANG Lian,XU Biao.Clinical Features and Prognosis of Patients with Takotsubo Cardiomyopathy[J].Advances in Cardiovascular Diseases,2019,(6):831.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.041]
[8]吕俊兴 许海燕.急性冠脉综合征危险评分的研究进展[J].心血管病学进展,2019,(9):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
LU Junxing,XU Haiyan.Risk Scores of Acute Coronary Syndrome[J].Advances in Cardiovascular Diseases,2019,(6):1224.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.010]
[9]程宏基 黄裕立 黄伟俊 李美君 童辉煜 申常造 谭宽 蔡福生 胡允兆.入院血糖水平不同的分组方法对急性心力衰竭患者远期预后影响的比较[J].心血管病学进展,2019,(9):1323.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.035]
CHENG Hongji,HUANG Yuli,HUANG Weijun,et al.Effect of Different Admission Blood Glucose Grouping Methods on the Prognosis of Acute Heart Failure Patients[J].Advances in Cardiovascular Diseases,2019,(6):1323.[doi:10.16806/j.cnki.issn.1004-3934.2019.09.035]
[10]罗正丽 李东泽 贾禹 陈力 万智.急性胸痛早期危险分层的研究进展[J].心血管病学进展,2020,(1):39.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.011]
LUO Zh engli,LI Dongze,JIA Yu,et al.Early Risk Stratification of Acute Chest Pain[J].Advances in Cardiovascular Diseases,2020,(6):39.[doi:10.16806/j.cnki.issn.1004-3934.2020.01.011]